Business Cipla remains confident after US FDA observations, says de-risking plan in place Updated : October 11, 2019 03:58 PM IST According to the company, the observations mainly centered on facilities, equipment and infrastructure. The share price fell up to 7.74 percent to touch its five-year low of Rs 389.6 on the NSE after the US regulator issued 12 observations to the plant. Subscribe to Moneycontrol PRO at just Rs.33/- per month for the first year. Use code SUPERPRO. Limited period offer. Available on Web and Android.